These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11981066)

  • 1. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis.
    Nakamura T; Ushiyama C; Hirokawa K; Osada S; Inoue T; Shimada N; Koide H
    Nephrol Dial Transplant; 2002 May; 17(5):798-802. PubMed ID: 11981066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
    Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
    J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia.
    Simons LA
    Am J Cardiol; 2002 Oct; 90(7):737-40. PubMed ID: 12356387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
    Dujovne CA; Knopp R; Kwiterovich P; Hunninghake D; McBride TA; Poland M
    Mayo Clin Proc; 2000 Nov; 75(11):1124-32. PubMed ID: 11075741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia.
    Yu WC; Chen CH; Tsao HM; Ding YA
    Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jun; 65(6):260-7. PubMed ID: 12201566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia].
    Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
    Rev Med Interne; 1999 Aug; 20 Suppl 3():393s-398s. PubMed ID: 10480191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
    Saunders E; Ferdinand K; Yellen LG; Tonkon MJ; Krug-Gourley S; Poland M
    J Natl Med Assoc; 2000 Jul; 92(7):319-26. PubMed ID: 10946527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
    Ridker PM; Rifai N; Lowenthal SP
    Circulation; 2001 Mar; 103(9):1191-3. PubMed ID: 11238259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia.
    Nakamura T; Ushiyama C; Hirokawa K; Osada S; Shimada N; Koide H
    Am J Nephrol; 2001; 21(6):449-54. PubMed ID: 11799261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
    Farnier M
    Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
    Stein E
    Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators.
    Rubinstein A; Maritz FJ; Soule SG; Markel A; Chajek-Shaul T; Maislos M; Tal S; Stolero D
    J Cardiovasc Risk; 1999 Dec; 6(6):399-403. PubMed ID: 10817086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S
    Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
    De Luis DA; Romero E; Aller R; Izaola O
    Clin Nutr; 2000 Oct; 19(5):367-70. PubMed ID: 11031077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
    Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
    Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis.
    Nakamura T; Ushiyama C; Suzuki Y; Osada S; Inoue T; Shoji H; Hara M; Shimada N; Koide H
    Nephron Clin Pract; 2003; 94(2):c33-9. PubMed ID: 12845235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine synaptopodin excretion is an important marker of glomerular disease progression.
    Kwon SK; Kim SJ; Kim HY
    Korean J Intern Med; 2016 Sep; 31(5):938-43. PubMed ID: 27604800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.